Attenuation of mouse acute colitis by naked hepatocyte growth factor gene transfer into the liver

Journal of Gene Medicine

Volumn 8, Issue 5, 2006, Pages 623-635

  Hanawa, Takayasu ^a   Suzuki, Kenji ^a   Kawauchi, Yusuke ^a   Takamura, Masaaki ^a   Yoneyama, Hiroyuki ^b   Han, Gi Dong ^a   Kawachi, Hiroshi ^a   Shimizu, Fujio ^a   Asakura, Hitoshi ^a   Miyazaki, Jun Ichi ^c   Maruyama, Hiroki ^a   Aoyagi, Yutaka ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

C Met; DSS colities; HGF; Inflammatory bowel disease; Naked gene transfer

Indexed keywords

BROXURIDINE; CYTOKINE; DEXTRAN SULFATE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 8; MESSENGER RNA; NAKED DNA; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATTENUATION; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; EROSION; FEMALE; GENE TARGETING; GENE THERAPY; GENERAL CONDITION IMPROVEMENT; INTESTINE EPITHELIUM CELL; INTESTINE EROSION; MOUSE; NICK END LABELING; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYMPTOM; WOUND HEALING;

ACUTE DISEASE; ANIMALS; COLITIS; DEXTRAN SULFATE; FEMALE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEPATOCYTE GROWTH FACTOR; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-18; LAC OPERON; LIVER; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PLASMIDS; RATS; RECOMBINANT PROTEINS; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33645993720     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.880     Document Type: Article

References (39)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-429.
2. Sands BE. Therapy of inflammatory bowel disease. Gastroenterology 2000; 118: S68-S82.
3. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 2001; 120: 622-635.
4. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002; 122: 1592-1608.
5. Targan SR, Hanauer Sb, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-1035.
6. Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004; 126: 989-996.
7. Playford RJ. Peptides and gastrointestinal mucosal integrity. Gut 1995; 37: 595-597.
8. Procaccino F, Reinshagen M, Hoffmann P, et al. Protective effect of epidermal growth factor in an experimental model of colitis in rats. Gastroenterology 1994; 107: 12-17.
9. Sinha A, Nightingale JMD, West KP, et al. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis. N Engl J Med 2003; 349: 350-357.
10. Boros P, Miller CM. Hepatocyte growth factor: a multifunctional cytokine. Lancet 1995; 345: 293-295.
11. Zarnegar R, Michalopoulos GK. The many faces of hepatocyte growth factor: from heptopoiesis to hematopoiesis. J Cell Biol 1995; 129: 1177-1180.
12. Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989; 342: 440-443.
13. Nishimura S, Takahashi M, Ota S, et al. Hepatocyte growth factor accelerates restitution of intestinal epithelial cells. J Gastroenerol 1998; 33: 172-178.
14. Tsuji S, Kawano S, Tsujii M, et al. Roles of hepatocyte growth factor and its receptor in gastric mucosa. A cell biological and molecular biological study. Dig Dis Sci 1995; 40: 1132-1139.
15. Nusrat A, Parkos CA, Bacarra AE, et al. Hepatocyte growth factor/scatter factor effects on epithelia. Regulation of intercellular junctions in transformed and nontransformed cell lines, basolateral polarization of c-met receptor in transformed and natural intestinal epithelia, and induction of rapid wound repair in a transformed model epithelium. J Clin Invest 1994; 93: 2056-2065.
16. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991; 251: 802-804.
17. Itoh H, Naganuma S, Takeda N, et al. Regeneration of injured intestinal mucosa is impaired in hepatocyte growth factor activator-deficient mice. Gastroenterology 2004; 127: 1423-1435.
18. Kitamura S, Kondo S, Shinomura Y, et al. Expression of heptocyte growth factor and c-met in ulcerative colitis. Inflamm Res 2000; 49: 320-324.
19. Ortega-Cava CF, Ishihara S, Kawashima K, et al. Hepatocyte growth factor expression in dextran sodium sulfate-induced colitis in rats. Dig Dis Sci 2002; 47: 2275-2285.
20. Tahara Y, Ido A, Yamamoto S, et al. Hepatocyte growth factor facilitates colonic mucosal repair in experimental ulcerative colitis in rats. J Pharmacol Exp Ther 2003; 307: 146-151.
21. Arthur G, Schwartz MZ, Kuenzler KA, Birbe R. Hepatocyte growth factor treatment ameliorates diarrhea and bowel inflammation in a rat model of inflammatory bowel disease. J Pediatr Surg 2004; 39: 139-143.
22. Hickman MA, Malone RW, Lehmann-Bruinsma K, et al. Gene expression following direct injection of DNA into liver. Hum Gene Ther 1994; 5: 1477-1483.
23. Paillard F. Naked DNA gene delivery to the liver. Hum Gene Ther 1997; 8: 1735-1736.
24. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999; 6: 1258-1266.
25. Sasaki S, Yoneyama H, Suzuki K, et al. Blockade of CXCL10 protects mice from acute colitis and enhances crypt cell survival. Eur J Immunol 2002; 32: 3197-3205.
26. M Noguchi, N Hiwatashi, Z Liu, T Toyota. Secretion imbalance between tumor necrosis factor and its inhibitor in inflammatory bowel disease. Gut 1998; 43: 203-209.
27. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255-256.
28. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferations in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419.
29. Ueki T, Kaneda Y, Tsutsui H, et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999; 5: 226-230.
30. Kuroiwa T, Kakishita E, Hamano T, et al. Hepatocyte growth factor ameliorates acute graft-versus-host disease and promotes hematopoietic function. J Clin Invest 2001; 107: 1365-1373.
31. Zhang G, Budker V, Wolff JA. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 1999; 10: 1735-1737.
32. Zhang G, Song YK, Liu D. Long-term expression of human alpha1-antitrypsin gene in mouse liver achieved by intravenous administration of plasmid DNA using a hydrodynamics-based procedure. Gene Ther 2000; 7: 1344-1349.
33. Miao CH, Thompson AR, Loeb K, et al. Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo. Mol Ther 2001; 3: 947-957.
34. Maruyama H, Higuchi N, Nishikawa Y, et al. High-level expression of naked DNA delivered to rat liver via tail vein injection. J Gene Med 2002; 4: 333-341.
35. Takayama H, LaRochelle WJ, Sharp R, et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A 1997; 94: 701-706.
36. Oh K, Iimuro Y, Takeuchi M, et al. Ameliorating effect of hepatocyte growth factor on inflammatory bowel disease in a murine model. Am J Physiol 2004; 288: 729-735.
37. Okayasu I, Hatakeyama S, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990; 98: 694-702.
38. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993; 69: 238-249.
39. Mukoyama T, Kanbe T, Murai R, et al. Therapeutic effect of adenoviral-mediated hepatocyte growth factor gene administration on TNBS-induced colitis in mice. Biochem Biophys Res Commun 2005; 329: 1217-1224.